View all news

    IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, FirstLine Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

    05/19/2021
    Download(opens in new window)PDF 219 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com